Clinical Trial Update: Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety, tolerability, and pharmacodynamics of KP104 in participants with thrombotic microangiopathy secondary to systemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus
• Thrombotic Microangiopathy

Drugs mentioned

• KP104 (KP104)

Snippet

Sponsor: Kira Pharmacenticals (US), LLC. | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: NOT_YET_RECRUITING